Risk of Fractures after StrokeBrown D.L.a · Morgenstern L.B.a, b · Majersik J.J.a · Kleerekoper M.c · Lisabeth L.D.a, b
aStroke Program, University of Michigan Medical School, bDepartment of Epidemiology, University of Michigan School of Public Health, and cSt. Joseph Mercy Hospital, Ann Arbor, Mich., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: The aim of this study was to determine the risk of fractures after stroke/transient ischemic attack (TIA) in relatively young patients. Methods: Administrative claims data were identified for patients aged 18 years and older hospitalized for stroke/TIA from 1997 to 2005 using ICD-9 codes. Fractures after stroke/TIA were identified for the same time period. Results: The median age was 56 years. Females represented 47%. There were 411 ischemic strokes, 195 TIAs and 36 intracerebral hemorrhages, as well as 46 fractures in 41 individuals. The risk of fracture after stroke/TIA was 1.2% at 30 days and 3.1% at 1 year. There was no significant difference in survival free from fracture between ischemic stroke and TIA cases (p = 0.8489). Conclusions: Patients with stroke/TIA, including men and younger patients, appear to be at risk for bone fractures.
© 2007 S. Karger AG, Basel
- Ramnemark A, Nyberg L, Lorentzon R, Olsson T, Gustafson Y: Hemiosteoporosis after severe stroke, independent of changes in body composition and weight. Stroke 1999;30:755–760.
- Jorgensen L, Jacobsen BK, Wilsgaard T, Magnus JH: Walking after stroke: does it matter? Changes in bone mineral density within the first 12 months after stroke – A longitudinal study. Osteoporos Int 2000;11:381–387.
- Ramnemark A, Nyberg L, Lorentzon R, Englund U, Gustafson Y: Progressive hemiosteoporosis on the paretic side and increased bone mineral density in the nonparetic arm the first year after severe stroke. Osteoporos Int 1999;9:269–275.
- Dennis MS, Lo KM, McDowall M, West T: Fractures after stroke: frequency, types, and associations. Stroke 2002;33:728–734.
- Ramnemark A, Nyberg L, Borssen B, Olsson T, Gustafson Y: Fractures after stroke. Osteoporos Int 1998;8:92–95.
- Hirose Ki, Tomiyama H, Okazaki R, Arai T, Koji Y, Zaydun G, Hori S, Yamashina A: Increased pulse wave velocity associated with reduced calcaneal quantitative osteo-sono index: possible relationship between atherosclerosis and osteopenia. J Clin Endocrinol Metab 2003;88:2573–2578.
- Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V: Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 2004;89:4246–4253.
- Hamerman D: Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies. QJM 2005;98:467–484.
- Kanis J, Oden A, Johnell O: Acute and long-term increase in fracture risk after hospitalization for stroke. Stroke 2001;32:702–706.
- Ramnemark A, Nilsson M, Borssen B, Gustafson Y: Stroke, a major and increasing risk factor for femoral neck fracture. Stroke 2000;31:1572–1577.
National Committee for Quality Insurance: HEDIS 2006. 2. Technical Specifications. Washington, National Committee for Quality Insurance, 2005.
- Whitson HE, Pieper CF, Sanders L, Horner RD, Duncan PW, Lyles KW: Adding injury to insult: fracture risk after stroke in veterans. J Am Geriatr Soc 2006;54:1082–1088.
- Saverino A, Del Sette M, Conti M, Ermirio D, Ricca M, Rovetta G, Gandolfo C: Hyperechoic plaque: an ultrasound marker for osteoporosis in acute stroke patients with carotid disease. Eur Neurol 2006;55:31–36.
- Sato Y, Kaji M, Metoki N, Satoh K, Iwamoto J: Does compensatory hyperparathyroidism predispose to ischemic stroke? Neurology 2003;60:626–629.
- Yamaguchi T, Sugimoto T, Yano S, Yamauchi M, Sowa H, Chen Q, Chihara K: Plasma lipids and osteoporosis in postmenopausal women. Endocr J 2002;49:211–217.
- Scheidt-Nave C, Bismar H, Leidig-Bruckner G, Woitge H, Seibel MJ, Ziegler R, Pfeilschifter J: Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab 2001;86:2032–2042.
- Cui LH, Shin MH, Chung EK, Lee YH, Kweon SS, Park KS, Choi JS: Association between bone mineral densities and serum lipid profiles of pre- and post-menopausal rural women in South Korea. Osteoporos Int 2005;16:1975–1981.
- Sato Y, Honda Y, Kunoh H, Oizumi K: Long-term oral anticoagulation reduces bone mass in patients with previous hemispheric infarction and nonrheumatic atrial fibrillation. Stroke 1997;28:2390–2394.
- Caraballo PJ, Gabriel SE, Castro MR, Atkinson EJ, Melton LJ III: Changes in bone density after exposure to oral anticoagulants: a meta-analysis. Osteoporos Int 1999;9:441–448.
- Jamal SA, Browner WS, Bauer DC, Cummings SR; Osteoporotic Fractures Research Group: Warfarin use and risk for osteoporosis in elderly women. Ann Intern Med 1998;128:829–832.
- Goldstein LB: Accuracy of ICD-9-CM coding for the identification of patients with acute ischemic stroke: effect of modifier codes. Stroke 1998;29:1602–1604.
- Fox KM, Reuland M, Hawkes WG, Hebel JR, Hudson J, Zimmerman SI, Kenzora J, Magaziner J: Accuracy of medical records in hip fracture. J Am Geriatr Soc 1998;46:745–750.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.